PharmaCyte Biotech, Inc. Announces Reverse Stock Split
Key Highlights
- ➤1-for-19 reverse split takes effect November 12, 2026, after market close
- ➤PMCB begins split-adjusted Nasdaq trading November 13 under new CUSIP
- ➤Outstanding shares fall from approximately 10,755,649 to approximately 566,087
- ➤Reverse split targets compliance with Nasdaq’s minimum bid price requirement
PharmaCyte’s common stock is expected to begin trading on a post-split adjusted basis on November 13, 2026
PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced that the board of directors of the Company approved a 1-for-19 reverse stock split (the “Reverse Split”) of the Company’s common stock. The Reverse Split was approved by the stockholders at the Company’s annual meeting of the stockholders held on March 30, 2026. The Reverse Split will legally take effect at 4:01 p.m. Eastern Time, on November 12, 2026. The Company’s common stock will open for trading under a new CUSIP number 71715X 302 on The Nasdaq Capital Market on November 13, 2026, on a split-adjusted basis under the current ticker symbol “PMCB.” The Reverse Split is intended to increase the per share trading price of the Company’s common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
Get started
Create a free account to read the full story.